The pros and cons of different prostanoids in the medical management of glaucoma

Current Opinion in Ophthalmology

Volumn 12, Issue 2, 2001, Pages 149-156

  Susanna Jr , Remo ^a   Medeiros, Felipe Andrade ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BETAXOLOL; BRIMONIDINE; DORZOLAMIDE; LATANOPROST; PROSTANOID; TIMOLOL; UNOPROSTONE ISOPROPYL ESTER;

ANGINA PECTORIS; ASTHMA; DRUG EFFICACY; DRUG INDUCED DISEASE; GLAUCOMA; HEADACHE; HUMAN; HYPERTRICHOSIS; INCIDENCE; INTRAOCULAR HYPOTENSION; INTRAOCULAR PRESSURE; PRIORITY JOURNAL; REVIEW; VERTIGO;

ANTIHYPERTENSIVE AGENTS; DINOPROST; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; OPHTHALMIC SOLUTIONS; PROGNOSIS; PROSTAGLANDINS; PROSTAGLANDINS F, SYNTHETIC; RANDOMIZED CONTROLLED TRIALS;

EID: 0035083670     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/00055735-200104000-00012     Document Type: Review

References (97)

1. The mechanism of action of prostaglandins on uveoscleral outflow
2. A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study
3. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma. A six-month, masked, multicenter trial in the United States
4. Effects on intraocular pressure and side effects of 0005% latanoprost applied once daily, evening or morning. A comparison with timolol
5. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension
6. A pooled-data analysis of three randomized, double-masked, six-month clinical studies comparing the intraocular pressure reducing effect of latanoprost and timolol
7. Latanoprost treatment for glaucoma: Effects of treating for 1 year and of switching from timolol
8. Latanoprost: Two years experience of its use in the United Kingdom
9. Efficacy and safety of latanoprost eye drops for glaucoma treatment: A 1-year study in Japan
10. Latanoprost: Experience of 2-year treatment in Scandinavia
11. A comparison of latanoprost and dorzolamide in patients with glaucoma and ocular hypertension: A 3-month, randomised study
12. Around-the-clock (circadian) intraocular pressure reduction with once-daily application of 0.005% latanoprost by itself or in combination with timolol
13. Comparison of 24-hour intraocular pressure reduction with two dosing regimens of latanoprost and timolol maleate in patients with primary open-angle glaucoma
14. Effect of timolol, latanoprost and dorzolamide on circadian IOP in glaucoma and ocular hypertension
15. Comparison of the intraocular pressure lowering effect of latanoprost and a fixed combination of timolol-pilocarpine eye drops in patients insufficiently controlled with beta-adrenergic antagonists
16. Intraocular pressure-lowering effects of latanoprost monotherapy versus latanoprost or pilocarpine in combination with timolol: A randomized, observer-masked multicenter study in patients with open-angle glaucoma
17. Comparison of latanoprost monotherapy to dorzolamide combined with timolol in patients with glaucoma and ocular hypertension. A 3-month randomized study
18. Substitution with latanoprost monotherapy or additional with dorzolamide in timolol treated patients. A randomized, multicenter study in Italy
19. Early phase II study of UF-021 ophthalmic solution in primary open-angle glaucoma or ocular hypertension patients
20. Phase II double-masked dose-determination study of UF-021 ophthalmic solution in primary open-angle glaucoma and ocular hypertension
21. Double-masked comparative of UF-021 and timolol ophthalmic solutions in patients with primary open-angle glaucoma or ocular hypertension
22. The effect of unoprostone isopropylate 0.120% vs. timolol maleate 0.5% on diurnal IOP
23. A comparison of the intraocular pressure-lowering effect of 0.5% timolol maleate and the docosanoid derivative of a PGF2 alpha metabolite, 0.12% unoprostone, in subjects with chronic open-angle glaucoma or ocular hypertension
24. Additive effect of latanoprost, a prostaglandin F2α analogue, and timolol in patients with elevated intraocular pressure
25. Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol
26. The additive intraocular pressure-lowering effect of latanoprost 0.005% daily once and pilocarpine 2% TID in patients with open-angle glaucoma or ocular hypertension: A 6-month, randomized, multicenter study
27. Comparison of the efficacy and safety of latanoprost 0.005% compared with brimonidine 0.2% or dorzolamide 2% when added to a topical beta-adrenergic blocker in patients with primary open-angle glaucoma or ocular hypertension
28. 2α
29. Interaction of PhXA41, a new prostaglandin analogue with pilocarpine. A study on patients with elevated intraocular pressure
30. Interaction of pilocarpine with latanoprost in patients with glaucoma and ocular hypertension
31. Additive effect of latanoprost to the combination of timolol and dorzolamide
32. Latanoprost for uncontrolled glaucoma in a compassionate case protocol
33. The additive effect of latanoprost to maximum-tolerated medications with low-dose, high-dose or no pilocarpine therapy
34. Effect of latanoprost as adjunctive therapy
35. Additive hypotensive effect of isopropyl unoprostone ophthalmic solution
36. Comparison of the intraocular pressure-lowering effect of latanoprost and timolol in patients with chronic angle closure glaucoma: A preliminary study
37. Efficacy of latanoprost as an adjunct to medical therapy for residual angle-closure glaucoma after iridectomy
38. Reduced intraocular pressure and increased ocular perfusion pressure in normal tension glaucoma: A review of short-term studies with three dose regimens of latanoprost treatment
39. Reduction of intraocular pressure with treatment of latanoprost once daily in patients with normal-pressure glaucoma
40. The effect of once-daily latanoprost on intraocular pressure and pulsatile ocular blood flow in normal tension glaucoma
41. A clinical evaluation of UF-021, a new prostaglandin-related compound, in low-tension glaucoma patients
42. Effect of latanoprost on intraocular pressure in steroid-induced glaucoma
43. A 12-month, randomized, double-masked study comparing latanoprost with timolol in pigmentary glaucoma
44. The effectiveness of latanoprost for the treatment of pediatric glaucoma
45. Use of latanoprost in the treatment of glaucoma associated with Sturge Weber syndrome
46. Latanoprost in glaucoma associated with Sturge-Weber syndrome: Benefits and side-effects
47. Latanoprost use in patients with uveitic glaucoma
48. The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color
49. Iris-color change developed after topical isopropyl unoprostone treatment
50. Iris pigmentation in two cases following topical instillation of isopropyl unoprostone
51. Latanoprost-induced iris color darkening: A case report with long-term follow-up
52. The fine structure of an iridectomy specimen from a patient with latanoprost-induced eye color change
53. Latanoprost stimulates eumelano-genesis in iridial melanocytes of cynomolgus monkeys
54. Effects of latanoprost on tyrosinase activity and mitotic index of cultured melanoma lines
55. Effect of prostaglandins A(2), E(1), F(2 alpha) and latanoprost on cultured human iridal melanocytes
56. Brief latanoprost rx induces hypertrichosis
57. Eyelash formation secondary to latanoprost treatment in a patient with alopecia
58. Increased eyelid pigmentation associated with use of latanoprost
59. Hypertrichosis caused by topical unoprostone
60. Latanoprost and herpes simplex keratitis
61. Latanoprost increases the severity and recurrence of herpetic keratitis in the rabbit
62. Differences in topical latanoprost and unoprostone on acute and recurrent herpetic keratitis in the rabbit
63. Adverse effects of latanoprost on patients with medically resistant glaucoma
64. Cystoid macular edema associated with latanoprost in aphakic and pseudophakic eyes
65. Latanoprost-associated cystoid macular edema
66. Cystoid macular edema associated with latanoprost use
67. Cystoid macular edema associated with the use of latanoprost
68. Latanoprost (Xalatan) induzierts Makulaodem
69. Adverse side effects associated with latanoprost
70. Latanoprost and cystoid macular oedema in a pseudophake
71. Cystoid macular edema associated with latanoprost therapy in a case series of patients with glaucoma or ocular hypertension
72. CME and anterior uveitis with latanoprost use
73. Cystoid macular edema and anterior uveitis associated with latanoprost use. Experience and incidence in a retrospective review
74. Latanorpost and cystoid macular edema: Is there a causal relation?
75. Latanoprost accelerates disruption of the blood-aqueous barrier and the incidence of angiographic cystoid macular edema in early postoperative pseudophakias
76. Latanoprost may trigger the biosynthesis of endogenous prostaglandins in early postoperative pseudophakias
77. Visually significant cystoid macular edema in pseudophakic and aphakic patients with glaucoma receiving latanoprost
78. Incide̊ncia de edema cistóide de mácula com o uso de Xalatan® em afácicos e pseudofácicos
79. Latanoprost 0.005% and anterior segment uveitis
80. Bilateral optic disk oedema associated with latanoprost
81. Bilateral optic disk oedema associated with latanoprost
82. Prostanoid-induced contraction of human bronchial smooth muscle is mediated by TP-receptors
83. 2I
84. Prostaglandin derivatives as ocular hypotensive agents
85. Prostaglandins as ocular hypotensive agents: Development of an analogue for glaucoma treatment
86. Latanoprost and respiratory function in asthmatic patients. Randomized, double-masked, placebo-controlled crossover evaluation
87. Effects of glaucoma medications on the cardiorespiratory and intraocular pressure status of newly diagnosed glaucoma patients
88. A comparison of the efficacy and safety of Xalatan vs. Rescula in patients with glaucoma or ocular hypertension. A double-masked, randomized trial comparing latanoprost with unoprostone in patients with open-angle glaucoma or ocular hypertension
89. A randomized double-masked crossover study comparing latanoprost 0.005% (Xalatan) with unoprostone 0.12% (Rescula) in patients with primary open angle glaucoma and ocular hypertension
90. A comparative study of latanoprost (Xalatan) and isopropyl unoprostone (Rescula) in normal and glaucomatous monkey eyes
91. A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol and betaxolol
92. Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension
93. The relation between diurnal tension variation and the water-drinking test
94. Contribuição ao estudo da pressão intra-ocular: Picos de pressão intra-ocular na curva diária de pressão e na prova de sobrecarga hidrica
95. The role of the water test in evaluation of glaucoma control
96. Normal tension glaucoma: The value of predictive tests
97. Transitory models of experimentally induced intraocular pressure changes in rabbit